BSX BOSTON SCIENTIFIC CORP
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 885725 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.9%
TTM net income YoY25.1%
TTM EPS YoY26.7%
Revenue 3-yr CAGR15.3%
Net income 3-yr CAGR41.8%
Margins
Gross margin69.1%
Operating margin18.7%
Net margin16.6%
FCF margin15.8%
EBITDA margin25.5%
Returns
ROE14.3%
ROA7.9%
ROIC (approx.)10.6%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets43.1%
Debt / equity0.47x
Current ratio1.36x
Interest coverage10.46x
Cash quality & payout
Operating cash flow / net income1.21x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue4.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $5.14B | $5.44B | $5.20B | $5.29B | $5.07B | $5.06B | $4.66B | $4.56B |
| Cost of revenue | $1.71B | $1.59B | $1.59B | $1.61B | $1.52B | $1.64B | $1.45B | $1.47B |
| Gross profit | $3.43B | $3.85B | $3.61B | $3.68B | $3.54B | $3.42B | $3.21B | $3.10B |
| R&D expense | $520.00M | $554.00M | $516.00M | $569.00M | $514.00M | $526.00M | $443.00M | $459.00M |
| SG&A expense | $1.68B | $1.80B | $1.78B | $1.83B | $1.74B | $1.72B | $1.60B | $1.61B |
| Operating income | $828.00M | $1.18B | $1.10B | $825.00M | $1.05B | $819.00M | $921.00M | $675.00M |
| Interest expense | $100.00M | $96.00M | $90.00M | $90.00M | $87.00M | $90.00M | $82.00M | $80.00M |
| Pretax income | $733.00M | $1.06B | $1.16B | $700.00M | $939.00M | $941.00M | $805.00M | $585.00M |
| Income tax | $153.00M | $155.00M | -$176.00M | $30.00M | $183.00M | $146.00M | $133.00M | $23.00M |
| Net income | $582.00M | $907.00M | $1.34B | $672.00M | $755.00M | $797.00M | $674.00M | $574.00M |
| EBITDA | $1.19B | $1.53B | $1.45B | $1.19B | $1.17B | $930.00M | $1.25B | $1.02B |
| EPS (basic) | 0.40 | 0.62 | 0.90 | — | 0.51 | 0.54 | 0.46 | — |
| EPS (diluted) | 0.40 | 0.61 | 0.90 | — | 0.51 | 0.53 | 0.45 | — |
| Weighted avg. shares (diluted) | 1.45B | 1.47B | 1.50B | — | 1.50B | 1.49B | 1.49B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $609.00M | $539.00M | $1.45B | $1.97B | $1.27B | $534.00M | $725.00M | $606.00M |
| Inventory | $3.32B | $3.23B | $3.12B | $2.94B | $2.92B | $2.86B | $2.87B | $2.81B |
| Current assets | $8.16B | $7.97B | $8.68B | $8.79B | $8.04B | $7.12B | $7.33B | $6.92B |
| PP&E, net | $4.18B | $4.13B | $4.06B | $4.04B | $3.79B | $3.46B | $3.39B | $3.29B |
| Goodwill | $18.74B | $18.64B | $18.54B | $18.28B | $18.21B | $18.08B | $17.34B | $17.09B |
| Intangibles | $6.86B | $6.92B | $7.06B | $7.02B | $7.16B | $7.26B | $6.57B | $6.68B |
| Total assets | $45.46B | $45.22B | $44.35B | $43.67B | $42.71B | $41.56B | $40.14B | $39.40B |
| Current liabilities | $5.98B | $6.43B | $4.57B | $5.44B | $5.33B | $5.19B | $5.06B | $6.40B |
| Short-term debt | $1.04B | $1.71B | $41.00M | $299.00M | $483.00M | $480.00M | $777.00M | $1.78B |
| Long-term debt | $10.91B | $10.91B | $10.99B | $11.14B | $11.12B | $11.11B | $10.53B | $8.97B |
| Total debt | $11.95B | $12.62B | $11.03B | $11.44B | $11.60B | $11.59B | $11.31B | $10.75B |
| Total liabilities | $19.59B | $20.04B | $18.25B | $19.20B | $19.08B | $18.91B | $17.69B | $17.39B |
| Shareholders' equity | $25.63B | $24.93B | $25.86B | $24.23B | $23.39B | $22.42B | $22.21B | $21.77B |
| Net debt | $11.34B | $12.09B | $9.58B | $9.47B | $10.32B | $11.05B | $10.58B | $10.14B |
| Cash flow statement | ||||||||
| Operating cash flow | $1.05B | $1.47B | $348.00M | $1.36B | $1.34B | $1.29B | $541.00M | $1.46B |
| Capital expenditure | $180.00M | $195.00M | $177.00M | $351.00M | $181.00M | $157.00M | $187.00M | $277.00M |
| Free cash flow | $868.00M | $1.28B | $171.00M | $1.01B | $1.16B | $1.13B | $354.00M | $1.18B |
| Investing cash flow | -$437.00M | -$1.96B | -$591.00M | -$512.00M | -$502.00M | -$1.13B | -$500.00M | -$3.70B |
| Financing cash flow | -$569.00M | -$410.00M | -$260.00M | -$184.00M | -$104.00M | -$340.00M | $233.00M | $214.00M |
| Depreciation & amortization | $361.00M | $355.00M | $351.00M | $365.00M | $117.00M | $111.00M | $325.00M | $348.00M |
| Stock-based compensation | $72.00M | $87.00M | $83.00M | $71.00M | $79.00M | $75.00M | $74.00M | $69.00M |
| Dividends paid | — | — | — | — | — | — | — | $0 |
| Share buybacks | $0 | — | — | — | $0 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.